From Dr. Pourhassan responding to questions... Would

New Post Public Reply Private Reply Replies (0) Message Board
DJknows
766
From Dr. Pourhassan responding to questions...

Would love to do what our scientists and experts suggest and we'll have a meeting shortly on that...

Patent Protection: have over 57 patents filed and protected....

Will let Dr. Fauci and Gilead speak about Gilead... they weren't given any special privileges... we were given special privileges

Talking to UK, Italy and Iran as well as other countries...

Will have 600K doses for 300K patients for two weeks

Woking on approval to bring Virologix to market... working on it all for all
indications... (own comment: was asked for timing but didn't say anything more specific)


Dr. Patterson:
Using diagnostics to show efficacy and safety ... and have clinical trials to show exactly what's proceeding, that's the elegance of how we're doing this as a group and seeing it on a day-to-day basis telling us we're on the right track... there's two levels o clinical significance... have to let the FDA do their things and we're looking at the data on how the drug works on Covid and saying the drug is doing what it's supposed to be doing... have great confidence about a positive outcome.

Pourhassan: got 15 for severe trial and maybe can get in there when we have 50...

Don't expect any major adverse effect based on HIV done already...

Patterson: nothing on the market that can say no renal, liver or serious adverse side effects on a patient... (Leronlimab can say that)

Both other meds from Genentech and ___ are piecemeal... these other approaches are just treating one aspect of the spectrum of alterations in Covid-19... at the end of the day, piecemeal approaches are not going to be the solution... in fact Dr. Fauci said the other day there needs to be an anti-inflamatory as well which sets up Leronlimab perfectly.

Pourhassan:
Board members are preparing and meeting to set up for eventual sales


Condition No. Patients Results
Very critically ill- 11- 4 were saved
Criticaly ill- 11- 10 either extubated
or improving
Severely ill- 17- No results on 2,
13 out of 15 either
discharged or improving
Mid-to-Moderate- 0- N/A
















CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 31

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 196

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Why Recurring Lawn Bare Patches Need More Than Seed

Updated Category News Views 26

A bald spot beside a backyard gate is rarely asking for another fistful of seed. Scott Jungles, a residential landscape maintenance expert with Good Natured Gardening in Charleston, frames the issue plainly: recurring turf loss is often evidence that something below, above, or across that small section of lawn is working against the grass. That is a useful bit of...

Continue Reading
LNG’s Coming Glut Could Gut Global Trading Profits

Updated Category News Views 118

A five-year LNG surplus is the sort of forecast that makes people nod politely today and panic much too late. Bain & Company is putting a hard edge on that risk: the global trading profit pool could slide from an estimated $20 billion in 2026 to roughly $5.5 billion a year during a 2030–34 glut, then potentially tip below zero once cancellation costs bite. That is not a...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 106

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Devicie Broadens Browser Security Across Device Fleets

Updated Category News Views 57

Browsers have quietly become the front door, side door, and occasionally the busted basement window of corporate security. Devicie’s newly expanded Edge for Business Reporting Connector tackles that uncomfortable reality by pulling browser security events from Windows, macOS, iOS, and Android into the same console customers use to oversee Microsoft Intune environments....

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 11

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 12

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 46

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading

Top 5 Most Recently Viewed Articles

Portal26 Welcomes Rick O'Rourke as New Chief Revenue Officer

Updated Category News Views 222

Portal26 Appoints Rick O'Rourke as Chief Revenue Officer Portal26, a leading generative AI adoption management platform, has officially appointed Rick O'Rourke as its new Chief Revenue Officer (CRO). Bringing over 20 years of expertise, O'Rourke's impressive track record is well-aligned with the company’s mission to innovate and thrive within the rapidly-evolving...

Continue Reading
Biocodex Microbiota Foundation's $50K Grant Opens for 2026

Updated Category News Views 286

Let’s Talk Microbiome Research Had a look at this, huh? The Biocodex Microbiota Foundation is rolling out $50,000 for gut microbiome studies in 2026. They’re celebrating ten years of giving researchers a leg-up, with $500K dished out to date. It’s good stuff, depending on how you slice it. This isn’t just free cash; it’s a bid to push boundaries in health and...

Continue Reading
Discover Triple Paste's New Products for Healthy Skin

Updated Category News Views 119

Experience Healthy, Glowing Skin with Triple Paste The winter months can take a toll on our skin, especially for babies and new moms. Recognizing this, Advantice Health, the company behind the beloved Triple Paste® diaper rash ointments, is excited to reveal their latest additions designed to nurture and protect delicate skin. With a focus on safety and effectiveness,...

Continue Reading
Celebrating Sarah Valentini: A Trailblazer in Entrepreneurship

Updated Category News Views 633

Sarah Valentini: A Beacon of Innovation and Leadership In the ever-evolving landscape of entrepreneurship, recognition stands as a testament to ambition and dedication. This year marks a significant milestone as the Entrepreneur Of The Year program celebrates its 40th anniversary, highlighting leaders who are not only ambitious but are redefining the future with their...

Continue Reading
Future Outlook of the Asset Performance Management Market

Updated Category News Views 177

Asset Performance Management Market: Growth Projections The global Asset Performance Management Market is witnessing remarkable growth. The market size is expected to rise significantly, projecting an increase from approximately USD 2.16 billion to around USD 3.55 billion, reflecting a compound annual growth rate (CAGR) of 10.5% over the forecast period. This growth...

Continue Reading